<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095757</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00027735</org_study_id>
    <secondary_id>WCI1671-09</secondary_id>
    <nct_id>NCT01095757</nct_id>
  </id_info>
  <brief_title>Evaluation of the Drug Plerixafor in Combination With Chemotherapy and G-CSF for Stem Cell Collection</brief_title>
  <official_title>Evaluation of Plerixafor (Mozobil ™, AMD3100) in Combination With Chemotherapy and G-CSF for CD34+ Cell Mobilization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether the addition of the drug plerixafor to treatment
      with chemotherapy and G-CSF can better activate your bone marrow stem cells to improve the
      chances of transplant. The study will look for the activation of a certain type of blood
      cell, called CD34+ cells in patients who receive plerixafor, chemotherapy and G-CSF. The
      investigators will follow the number of patients that achieve the target numbers of CD34+
      cells. The number of patients achieving the target level of CD34+ cells, and the total number
      of CD34+ cells, will be compared to the numbers in previous studies testing just chemotherapy
      and G-CSF, without plerixafor.

      The investigators will also test the safety of the combination of plerixafor with
      chemotherapy and G-CSF and look at the success of the transplantation after 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis</measure>
    <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients Achieving &gt;= 3 X 10^6 CD34+ Cell/Kg</measure>
    <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Number of Days for Engraftment (Engraftment Defined as Absolute Neutrophil Count&gt;500)</measure>
    <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Myeloma</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Plerixafor + Chemo and G-CSF</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Plerixafor</intervention_name>
    <description>240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
    <arm_group_label>Plerixafor + Chemo and G-CSF</arm_group_label>
    <other_name>Mozobil</other_name>
    <other_name>AMD3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-70 years

          2. Multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) patients in first or second
             complete or partial remission

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          4. Up to 3 prior treatment regimens

          5. Meet all eligibility requirements for autologous transplant

          6. Adequate marrow function defined as white blood cells (WBC) &gt;3,000; ANC &gt;1,500/mm3;
             platelets &gt;75,000/mm3

          7. Adequate renal function defined as creatinine clearance &gt; 30 mL/min by Cockcroft-Gault

          8. Adequate liver function defined as aspartate aminotransferase (AST)/alanine
             aminotransferase (ALT)/bilirubin &lt; 2 times upper limit of normal

          9. Able to provide informed consent

         10. Women not pregnant and agree to use contraception

        Exclusion Criteria:

          1. High risk co-morbidities for acute treatment complications (e.g., symptomatic coronary
             artery disease)

          2. Brain metastases or carcinomatous meningitis

          3. Previous treatment with high dose chemotherapy and autologous transplant

          4. Previous attempt to collect B-hematopoietic progenitor cells (HPCs) following
             mobilization with growth factors alone, growth factors and chemotherapy, or plerixafor
             and growth factors

          5. Acute infection or unexplained fever &gt;38°C

          6. Weight &gt; 175% of ideal body weight as defined by the Devine equation

          7. Experimental therapy within 4 weeks

          8. Cytokine administration in the previous 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edmund Waller, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University Winship Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lazarus HM, Loberiza FR Jr, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb;27(4):387-96.</citation>
    <PMID>11313668</PMID>
  </reference>
  <reference>
    <citation>Lemoli RM, Martinelli G, Zamagni E, Motta MR, Rizzi S, Terragna C, Rondelli R, Ronconi S, Curti A, Bonifazi F, Tura S, Cavo M. Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. Blood. 2000 Apr 1;95(7):2234-9.</citation>
    <PMID>10733490</PMID>
  </reference>
  <reference>
    <citation>Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 1;24(19):3187-205. Epub 2006 May 8.</citation>
    <PMID>16682719</PMID>
  </reference>
  <reference>
    <citation>Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni AM. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1989 Nov 1;74(6):1905-14.</citation>
    <PMID>2478216</PMID>
  </reference>
  <reference>
    <citation>Cassens U, Momkvist PH, Zuehlsdorf M, Mohr M, Kienast J, Berdel WE, Sibrowski W. Kinetics of standardized large volume leukapheresis (LVL) in patients do not show a recruitment phenomenon of peripheral blood progenitor cells (PBPC). Bone Marrow Transplant. 2001 Jul;28(1):13-20.</citation>
    <PMID>11498739</PMID>
  </reference>
  <reference>
    <citation>Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion. 2004 May;44(5):777-84.</citation>
    <PMID>15104662</PMID>
  </reference>
  <reference>
    <citation>Hicks ML, Lonial S, Langston A, Flowers C, Roback JD, Smith KJ, Mossavi Sai S, Teagarden D, Hamilton ES, Waller EK, Kaufman J. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells. Transfusion. 2007 Apr;47(4):629-35. Erratum in: Transfusion. 2007 May;47(5):952. Kaufman, Jonathan [added].</citation>
    <PMID>17381621</PMID>
  </reference>
  <reference>
    <citation>Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK. Effectiveness and cost analysis of &quot;just-in-time&quot; salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion. 2011 Oct;51(10):2175-82. doi: 10.1111/j.1537-2995.2011.03136.x. Epub 2011 Apr 14.</citation>
    <PMID>21492180</PMID>
  </reference>
  <reference>
    <citation>Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007 Sep;21(9):2035-42. Epub 2007 Jun 21.</citation>
    <PMID>17581613</PMID>
  </reference>
  <reference>
    <citation>Mazumder A, Kaufman J, Niesvizky R, Lonial S, Vesole D, Jagannath S. Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients. Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. Epub 2007 Nov 22.</citation>
    <PMID>18033320</PMID>
  </reference>
  <reference>
    <citation>Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, Boesiger J, Torloni AS, Fonseca R, Bergsagel PL. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia. 2008 Jun;22(6):1282-4. doi: 10.1038/sj.leu.2405100. Epub 2008 Jan 24.</citation>
    <PMID>18216870</PMID>
  </reference>
  <reference>
    <citation>Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med. 2011 Feb 14;208(2):251-60. doi: 10.1084/jem.20101700. Epub 2011 Jan 31.</citation>
    <PMID>21282380</PMID>
  </reference>
  <reference>
    <citation>Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J, Arenzana-Seisdedos F, Magerus A, Caruz A, Fujii N, Nagler A, Lahav M, Szyper-Kravitz M, Zipori D, Lapidot T. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000 Dec;106(11):1331-9.</citation>
    <PMID>11104786</PMID>
  </reference>
  <reference>
    <citation>Jung Y, Wang J, Schneider A, Sun YX, Koh-Paige AJ, Osman NI, McCauley LK, Taichman RS. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone. 2006 Apr;38(4):497-508. Epub 2005 Dec 5.</citation>
    <PMID>16337237</PMID>
  </reference>
  <reference>
    <citation>DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10.</citation>
    <PMID>19363221</PMID>
  </reference>
  <reference>
    <citation>Kaufman JL, Flowers CR, Rados KD, Calandra GB, Vose JM, Hewes LB, Lonial S, Langston AA, Khoury HJ, Lechowicz MJ, Waller EK. A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion. 2013 Jan;53(1):76-84. doi: 10.1111/j.1537-2995.2012.03719.x. Epub 2012 May 25.</citation>
    <PMID>22624594</PMID>
  </reference>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>September 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2014</results_first_posted>
  <last_update_submitted>September 16, 2014</last_update_submitted>
  <last_update_submitted_qc>September 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Edmund Waller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Stem cell transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>JM 3100</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Plerixafor + Chemo and G-CSF</title>
          <description>Patients who receive a combination of Plerixafor, chemotherapy and granulocyte-colony stimulating factor (G-CSF).
Plerixafor : 240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target cluster of differentiation 34 (CD34) cell dose has been reached.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Plerixafor + Chemo and G-CSF</title>
          <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Multiple Myeloma (MM), n = 17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="33" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma, n = 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="38" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis</title>
        <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Myeloma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
          <group group_id="O2">
            <title>Lymphoma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving Greater Than or Equal to 5 x 10^6 of CD34+ Cells/kg in a Single Day of Apheresis</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Average Number of Days for Engraftment (Engraftment Defined as Absolute Neutrophil Count&gt;500)</title>
        <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Myeloma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
          <group group_id="O2">
            <title>Lymphoma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Number of Days for Engraftment (Engraftment Defined as Absolute Neutrophil Count&gt;500)</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="1.62"/>
                    <measurement group_id="O2" value="12.105" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patients Achieving &gt;= 3 X 10^6 CD34+ Cell/Kg</title>
        <time_frame>Within the first 4 days following the first dose of Plerixafor</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Multiple Myeloma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
          <group group_id="O2">
            <title>Lymphoma</title>
            <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving &gt;= 3 X 10^6 CD34+ Cell/Kg</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Plerixafor + Chemo and G-CSF</title>
          <description>Patients who receive a combination of Plerixafor, chemotherapy and G-CSF.
Plerixafor : 240 µg/kg subcutaneous injection on the day that the ANC is &gt; 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Grade 1/2</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia Over Grade 2</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="45"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edmund Waller</name_or_title>
      <organization>Winship Cancer Institute Emory University</organization>
      <phone>404-727-4995</phone>
      <email>ewaller@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

